A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC）

NCT05025631 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
29
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Zhen-Yu Ding